/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
TSX VENTURE EXCHANGE: AVI
QUEBEC CITY, March 10 /CNW Telbec/ - Advitech Inc. ("Advitech" or the "Corporation") (TSX Venture Exchange: AVI) announces today that the Natural Health Products Directorate (NHPD) has issued to Advitech, on March 8, 2010, a Natural Product Number (NPN) for one of its main products, XP-828L/Dermylex. The issuance of a product licence for XP-828L/Dermylex means that the product has been assessed by Health Canada and has been found to be safe, effective and of high quality under its recommended conditions of use.
As a result, for XP-828L/Dermylex, the approved claim authorized by the NHPD to appear on the product label is: "Clinically proven. Helps improve the symptoms of psoriasis".
"The issuance of this NPN is significant for Advitech as it will allow the Corporation to distribute XP-828L/Dermylex in Canada and in many other countries in which a NPN is mandatory for the registration of a Canadian Natural Health Product" stated Michael Stangel, President and Chief Executive Officer of Advitech. He added "This will allow us to finalize the registration of XP-828L/Dermylex in many countries where our status was pending upon obtaining the NPN and allow us to generate additional sales related to this issuance in the upcoming months. To our knowledge, XP-828L is the only natural health product that has been proven to help psoriasis patients and for which a NPN has been granted."
Advitech first applied for a Product Licence Application for XP-828L in December 2007. XP-828L is marketed as Dermylex in Canada.
ABOUT ADVITECH INC.
Advitech, which includes its subsidiary Botaneco Specialty Ingredients since November 20, 2009, is a health sciences and technology company developing, manufacturing and marketing proprietary natural ingredients and formulations for oral and topical applications that have been clinically proven to be safe and effective for improving skin health and well being. The Corporation's products are based on three technological platforms which are: i) a superior multi-functional emulsification delivery system derived from plant seed oleosomes for formulation application in the topical cosmetic, OTC, Rx and natural personal care specialty ingredient markets, ii) XP-828L for immune mediated inflammatory disorders, and iii) IM for anti-aging and wound healing. Advitech produces Hydresia(TM), a natural plant derived specialty ingredient which offers immediate moisturization advantages, formulating cost savings and excellent product aesthetics in a variety of product applications, Dermylex(R) for the treatment of mild-to-moderate psoriasis, and Nudremyl(TM) which acts on skin reconstruction, cellular regeneration and skin structure. More information is available and can be accessed at www.advitech.com and www.botaneco.ca.
This press release contains forward-looking statements, which reflect the Corporation's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE ADVITECH INC.
For further information: For further information: Michael Stangel, President and Chief Executive Officer, Advitech Inc., (418) 686-7498, (215) 604-0631